United Therapeutics, Liquidia settle Yutrepia patent litigation and agree to dismiss cases
UTHR•United Therapeutics and Liquidia settled multiple patent disputes tied to Yutrepia sales and labeling. Liquidia agreed to pay $330.4 million, while United Therapeutics will pay Liquidia $10 million to resolve a separate case.
1. Settlement payments
Liquidia must pay United Therapeutics $185 million within 30 business days for past PH-ILD sales from June 2, 2025, through execution of the settlement. It also agreed to pay $145.4 million in two installments due by Jan. 31, 2027, and Apr. 30, 2027.
2. Separate case and remaining claims
United Therapeutics will pay Liquidia $10 million to resolve a separate New Jersey case involving Sandoz and RareGen. Claims against former Liquidia executive Robert Roscigno as an individual remain pending and were excluded from the releases.
